Ivo Abraham, PhD, RN

Professor of Practice

Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan).  He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.

For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.  

More recently, frustrated by the abundance of evidence but clinicians’ persistent low adoption of evidence-based guidelines, he and his colleagues started examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.

He has (co-)authored 260+ articles and 60+ chapters, and has (co-)edited 29 books, monographs, and journal issues. Since 1984, his research has been funded by federal funding agencies, foundations, and corporations.   He has served as appointed ad hoc reviewer for the NIH, the NIMH, and the AHRQ. He currently serves as an expert adviser to the Innovative Medicines Initiative, a joint 2 billion euro undertaking of the European Union and the biopharmaceutical industry to stimulate innovation in human therapeutics.

His educational and scientific honors and awards include an Invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University.

View UA Profile

Education & Post Graduate Training: 

BS, Nursing, Katholieke Hogeschool Leuven (Leuven, Belgium)
MS, Psychiatric-Mental Health Nursing, University of Michigan
PhD, Clinical Research, University of Michigan 

Select Publications


Alkhushaym N, Almutairi AR, Althagafi A, et al. "Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis." Expert Opin Drug Saf. 2020;19(3):327-334. PMID: 31928106
Alkhatib NS, Erstad B, Ramos K, et al. "Pricing methods in outcome-based contracting: δ3: reference-based pricing." J Med Econ. 2020;23(11):1230-1236. PMID: 32845191
Alhifany AA, McBride A, Almutairi AR, et al. "Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis." Support Care Cancer. 2020;28(3):1031-1039. PMID: 31823054
Alkhatib NS, Bhattacharjee S, McBride A, et al. "Pricing methods in outcome-based contracting: δ4: safety-based pricing." J Med Econ. 2020;23(11):1237-1245. PMID: 32845205
Oh M, McBride A, Yun S, et al. "Response to Yang, Shi, Wang et al." J Natl Cancer Inst. 2020;112(4):428. PMCID: PMC7156932  PMID: 31424546
Alkhatib NS, McBride A, Bhattacharjee S, et al. "Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing." J Med Econ. 2020;23(11):1246-1255. PMID: 32845204
Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. "Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis." Front Oncol. 2020;10:91. PMCID: PMC7033582  PMID: 32117745
Alkhatib NS, Slack M, Bhattacharjee S, et al. "Pricing methods in outcome-based contracting: δ6: adherence-based pricing." J Med Econ. 2020;23(11):1256-1265. PMID: 32845209
McBride A, Krendyukov A, Mathieson N, et al. "Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma." J Med Econ. 2020;23(1):28-36. PMID: 31433700
Alkhatib NS, McBride A, Slack M, et al. "Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)." J Med Econ. 2020;23(11):1266-1272. PMID: 32845180